To test this hypothesis, we examined whether the myeloid-specific deletion of Prmt2 would impair the regression of atherosclerosis in normoglycemic conditions, thus mimicking the decrease in the regression of atherosclerosis in WT mice under diabetic conditions. Here, PRMT2 is linked to atherosclerosis.